Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Group (CAN) has secured a $50 million loan from National Australia Bank (NAB) to fund the first stage expansion of its Mildura Facility
  • The company is currently expanding its facility to increase its dried cannabis flower production
  • Site construction is expected to commence in February 2021, with the first product to be processed and released by March the following year
  • Once completed, the first stage will provide Cann with the capacity to produce 12,500 kilograms of the dried flower every year
  • On the market this morning, Cann is up 12.9 per cent and is trading for 35 cents per share

Cann Group (CAN) has secured a $50 million loan from National Australia Bank (NAB).

The funds will be used to complete the first stage of Cann’s medicinal cannabis production site near Mildura.

The company is currently expanding its facility to expand the production of dried cannabis flowers every year, using controlled environment greenhouse technology.

Cann said the new loan will clear a pathway to commence construction at the Mildura site, with work expected to begin in February next year. The first stage will take around nine months to build, with the first product to be processed and released by March 2022.

Once completed, Mildura’s first stage will allow Cann to produce around 12,500 kilograms of the dry flower every year.

All up, the first stage is expected to cost $112 million, but Cann has already spent around $53 million to fund on-site works and the facility superstructure. In July, the company received nearly $2 million under the Victorian Government’s regional jobs fund, which will contribute to the project.

CEO Peter Crock said increasing production at Mildura is an important step in Cann’s plan to produce medicinal cannabis at scale.

“The facility will utilise world-leading technology, providing Cann with a globally competitive unit price based on substantial economies of scale,” he said.

“Securing the support of a tier one bank is a strong validation of our strategic growth plans. Given the building demand for our products, we have the confidence to immediately ramp up production as soon as the facility is ready,” he added.

Final documents for the loan are scheduled for completion within the next month.

On the market this morning, Cann is up 12.9 per cent and is trading for 35 cents per share at 12:05 pm AEDT.

CAN by the numbers
More From The Market Online

PainCheck receives European patent for pain assessment technology

PainCheck®, developer of the world’s first smartphone-based pain assessment and monitoring application, has been granted a…

Bailador invests in Updoc digital healthcare platform

Bailador Technology Investments (ASX:BTI) has announced a $20million investment in Venture Startups International (Updoc).

Cleo Diagnostics reports its ovarian cancer blood tests superior to ultrasound

Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.